ImmunityBio Inc. (NASDAQ:IBRX) is one of the 13 Stocks Under $5 With High Upside Potential. ImmunityBio Inc. (NASDAQ:IBRX) ...

ImmunityBio, Inc. today announced results presented at ASCO 2025 of the first known treatment for lymphopenia with ANKTIVA and CAR-NK therapy. This data supports that reversal of lymphopenia, a ...

Association of lymphopenia rescue and CA19-9 levels with overall survival following IL-15 superagonist N-803 and PD-L1 t-haNK chemo-immunotherapy for 3rd line or greater metastatic pancreatic cancer.

Background: Lymphopenia is known to be a negative prognostic marker for NHL and hematological malignancies, recent observational studies evaluated the presence of lymphopenia and its impact in solid ...

The analysis of 11,427 Veterans Administration (VA) hospital patients with multiple myeloma (MM) reveals that lymphopenia affects 53% of patients at diagnosis. The median overall survival was 2.7 ...

CULVER CITY, Calif., June 03, 2025--ImmunityBio, Inc. (NASDAQ: IBRX) today announced results presented at ASCO 2025 of the first known treatment for lymphopenia with ANKTIVA and CAR-NK therapy.

The lymphopenia opportunity provides an attractive valuation, even when risk-adjusted. The FDA's recent compassionate use authorisation could draw more attention to this area of treatment, which ...

Lymphopenia—the loss of key immune cells such as NK, CD4+, and CD8+ T cells—is a common side effect of chemotherapy 1, radiation 2,3, and some immunotherapies 4.

Treatment-induced lymphopenia can be a consequence of radiation therapy, chemotherapy and certain immunotherapies, as well as steroids. Anktiva is designed specifically to address Bacille Calmette ...